CTI BioPharma Corp. (NASDAQ:CTIC)

CAPS Rating: 1 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Recs

3
Player Avatar dbbfool63 (23.31) Submitted: 8/27/2009 6:28:48 PM : Outperform Start Price: $47.70 CTIC Score: -193.97

Good entry point for mid to long term.

I couldn't get in until it got above a dollar to rate it although been watching since .o7/shr.

Probably could of got in lower, but lost track watching others.

Featured Broker Partners


Advertisement